Unlabelled: Despite the recognition of bariatric surgery as the only effective method of weight reduction, we remain in search of minimally invasive methods, both for the treatment of obesity and preparation of patients for surgical procedures. The aim of the study was to determine intragastric balloon (Allergan) implantation results as the only method of treating obesity, and patient preparation for further stages of abdominal hernia operations, as well as other surgical procedures.
Material And Methods: The study presented own results considering the use of Bioenteric Intragastric Balloons (BIB system) in the treatment of pathological obesity, and preparation of patients for bariatric surgery and abdominal hernia operations. The study group comprised 18 female and 7 male patients. Average patient age amounted to 50.6 and 54 years, respectively. Indications for intragastric balloon insertion were as follows: preparation for hernia (10 cases) and bariatric (5 patients) operations, and weight reduction management (8 patients). In two cases the implantation of the intragastric balloon served the preparation for gynecological and orthopedic (vertebral column) operations. One female patient was prepared for both bariatric and hernial surgery. The procedure was performed under general anesthesia. Statistical analysis considered 22 patients (one female patient was excluded from analysis, due to death, two other were excluded because of lack of sufficient data).Results. In case of two patients the intragastric balloon system was removed before 6 months had elapsed because of intolerance. One female patient died during the observation period for reasons not related to the procedure. The obtained BMI reduction ranged between 2 and 6 kg/m2, which amounted to a maximum weight loss of 24 kg. In one patient a weight gain of 2 kg was observed. Considering patients prepared for abdominal hernia operations weight reduction was greater and better maintained after the removal of the BIB system.
Conclusions: According to the authors of the presented study the intragastric balloon serves its role as a bridge to bariatric procedures and weight reduction, before planned extensive postoperative hernia operations. The use of the intragastric balloon only to reduce weight has no medical and economic justification.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2478/v10035-011-0028-2 | DOI Listing |
Obes Surg
January 2025
Hamad Medical Corporation, Doha, Qatar.
Background: Acute pancreatitis (AP) is a rare but serious complication of intragastric balloon (IGB) therapy. Despite the popularity of IGBs for weight loss, the incidence and risk factors of AP post-IGB insertion are not well understood. This study aimed to identify potential predictors and risk factors of AP in IGB patients.
View Article and Find Full Text PDFJ Metab Bariatr Surg
December 2024
Department of General Surgery, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield, Yorkshire, United Kingdom.
Purpose: We aimed to assess outcomes in patients undergoing sequential intragastric balloon (IGB) treatment for obesity.
Materials And Methods: Consecutive patients who underwent treatment between May 2014 and February 2023 were identified. We recorded outcomes including: weight at 3-monthly intervals, progression to definitive bariatric procedure and morbidity.
Pharmaceuticals (Basel)
November 2024
Biomedical Research Centre, University Hospital Hradec Kralove, 500 05 Hradec Kralove, Czech Republic.
Tacrine is a centrally active non-competitive reversible acetylcholinesterase inhibitor. It also exerts antagonising activity against -methyl-D-aspartate receptors. Tacrine was approved for the treatment of Alzheimer's disease in 1993, but was withdrawn from clinical use in 2013 because of its hepatotoxicity and gastrointestinal side effects.
View Article and Find Full Text PDFProc (Bayl Univ Med Cent)
October 2024
Department of Gastroenterology and Hepatology, The University of Florida College of Medicine - Jacksonville, Jacksonville, Florida, USA.
Background: Endoscopic bariatric interventions are viable alternatives to traditional weight loss surgeries for patients with a body mass index between 30 and 40 kg/m. While studies have explored the impact of intragastric balloons on obesity and weight reduction, comprehensive data on real-world device-related complications and failures are limited. This study aimed to investigate mechanical failures leading to patient adverse events reported to the US Food and Drug Administration.
View Article and Find Full Text PDFClin Pract Cases Emerg Med
November 2024
Texas Tech University Health Sciences Center at El Paso, Department of Emergency Medicine, El Paso, Texas.
Introduction: More than 40% of Americans are considered obese, resulting in annual healthcare costs estimated at $173 billion., Various interventions exist to address obesity including lifestyle modification, medications, and several surgical options. A novel ingestible intragastric balloon that self-deflates and is excreted approximately four months post-ingestion is being used in other countries such as Australia, Mexico, and several European countries.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!